Model-informed dose optimization of etrasimod in ulcerative colitis across CYP2C9 genotypes and hepatic impairment.
AIMS Etrasimod is an oral sphingosine-1-phosphate receptor modulator approved for moderate-to-severe ulcerative colitis. The impact of CYP2C9 polymorphisms and hepatic impairment on etrasimod exposure remains unclear. This study aimed to characterize their effects and identify clinically relevant dose adjustment strate...